Influenza Vaccines in the United States – Market Size, Trends, Opportunities and Growth Potential
The United States influenza vaccines market size is anticipated to observe tremendous growth projections during 2019 - 2025.
The prominent factors that are expected to contribute to the growth of the US Influenza vaccines market during the forecast period:
The report contains a deep analysis of the US influenza vaccines market with size in terms of both value and volume of the US influenza vaccines market. The report provides clear insight into current and future developments of the United States influenza vaccines market. The report also explores detailed analysis of the children and adults vaccinated with influenza vaccines in United States from 2013 to 2018 and forecasts to 2025. The report also details the latest information about the influenza vaccines production, supply, and allocation by major companies in the United States.
A comprehensive analysis has been done on pricing, distribution & demand and effectiveness of the influenza vaccines in the United States. It also provides a deep and thorough evaluation of the distribution channel and technique of the influenza vaccination. Furthermore, this topical report describes the features reimbursement pattern and offers a clear view of the regulatory framework. Additionally, the report comprises assessment of clinical trials, reviews promising influenza vaccines in the clinical development and rapid diagnostic testing for the management of influenza. Key trends in terms of collaboration, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also examines the main market growth driving and restraining forces and also gives an all-round future outlook through 2025.
The report also provides comprehensive profiles of the dominant players in the country’s influenza vaccines market such as Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca with important details on companies’ vaccines portfolio, sales, strategies, and the latest developments. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, and Biondvax Pharmaceuticals Ltd, are making novel technology-based influenza vaccines which are likely to affect the market share during the forecast period.
Key Topics Covered in the Report:
The prominent factors that are expected to contribute to the growth of the US Influenza vaccines market during the forecast period:
- Increased Disease Awareness
- Approval/launches of the New Influenza Vaccines
- Expanded Recommendations by Governmental and Advisory Bodies to be Vaccinated against Influenza Vaccines
- Introduction of the Quadrivalent Influenza Vaccines
The report contains a deep analysis of the US influenza vaccines market with size in terms of both value and volume of the US influenza vaccines market. The report provides clear insight into current and future developments of the United States influenza vaccines market. The report also explores detailed analysis of the children and adults vaccinated with influenza vaccines in United States from 2013 to 2018 and forecasts to 2025. The report also details the latest information about the influenza vaccines production, supply, and allocation by major companies in the United States.
A comprehensive analysis has been done on pricing, distribution & demand and effectiveness of the influenza vaccines in the United States. It also provides a deep and thorough evaluation of the distribution channel and technique of the influenza vaccination. Furthermore, this topical report describes the features reimbursement pattern and offers a clear view of the regulatory framework. Additionally, the report comprises assessment of clinical trials, reviews promising influenza vaccines in the clinical development and rapid diagnostic testing for the management of influenza. Key trends in terms of collaboration, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also examines the main market growth driving and restraining forces and also gives an all-round future outlook through 2025.
The report also provides comprehensive profiles of the dominant players in the country’s influenza vaccines market such as Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca with important details on companies’ vaccines portfolio, sales, strategies, and the latest developments. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, and Biondvax Pharmaceuticals Ltd, are making novel technology-based influenza vaccines which are likely to affect the market share during the forecast period.
Key Topics Covered in the Report:
- The Market Size of the United States Influenza Vaccines Market
- Scrutinizes the US Overall Persons Being Vaccinated with Influenza Vaccines
- Scrutinizes the US Children Being Vaccinated with Influenza Vaccines
- Scrutinizes the US Adults Being Vaccinated with Influenza Vaccines
- Provides Comprehensive Insights on the Latest Pricing Trends and Analysis
- Includes a Detailed Analysis of the US Influenza Vaccines Production, Supply, and Allocation (By Companies)
- Delivers a Complete Overview of the US Influenza Vaccines Distribution and Demand
- Examines the Effectiveness of the Influenza Vaccines in the United States
- Detailed Assessment of the Rapid Diagnostic Testing for the Management of Influenza
- Thoroughly Evaluates of the Distribution Channel and Technique of the Influenza Vaccination in the United States
- Detailed Insights of the Regulatory Framework, Features Reimbursement Patterns of the US Influenza Vaccines
- Provides Key Trends with Respect to Collaboration, Merger & Acquisition, Distribution, Exclusive and Licensing Agreement
- An Insightful Analysis of the Promising Influenza Vaccines in the Clinical Development
- Reviews Most Recent Clinical Trials of the Influenza Vaccines
- Investigates the Key Growth Drivers and Restraints of the US Influenza Vaccines Market
- A Comprehensive List of Key Market Players Along with the Analysis of their Current Vaccines Portfolios, Sales Value Analysis, and Recent Development
- What is the size of the influenza vaccines market in the United States?
- How many persons being vaccinated with influenza vaccines in the US during 2013 – 2025?
- What are the key drivers and restraints in the current market?
- What are the various influenza vaccines available in the United States?
- How is the market predicted to develop in the future?
- Who are the key players in this market space?
1. EXECUTIVE SUMMARY
2. UNITED STATES INFLUENZA VACCINES MARKET SIZE & ANALYSIS (2013 - 2025)
3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2013 - 2025)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES INFLUENZA VACCINES MARKET
4.1 Market Drivers
4.2 Market Restraints
5. UNITED STATES INFLUENZA VACCINES PRICING TRENDS & ANALYSIS
6. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES)
7. UNITED STATES INFLUENZA VACCINES DISTRIBUTION & DEMAND (2010 - 2019)
8. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES (2004 – 2019)
9. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA
10. DISTRIBUTION CHANNEL & TECHNIQUE OF INFLUENZA VACCINATION IN UNITED STATES
11. UNITED STATES INFLUENZA VACCINES REIMBURSEMENT POLICIES & REGULATORY SYSTEM
11.1 Reimbursement Policies
11.2 Regulation System
12. MAJOR DEALS IN THE INFLUENZA VACCINES MARKET
12.1 Merger & Acquisitions
12.2 Collaboration Deal
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Distribution Agreement
13. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT
14. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY
14.1 Year 2018
14.2 Year 2017
15. KEY COMPANIES ANALYSIS
15.1 Sanofi Pasteur
15.1.1 Business Overview
15.1.2 Influenza Vaccines Portfolio
15.1.3 Influenza Vaccines Sales Value Analysis
15.1.4 Recent Development
15.2 GlaxoSmithKline (GSK)
15.2.1 Business Overview
15.2.2 Influenza Vaccines Portfolio
15.2.3 Influenza Vaccines Sales Value Analysis
15.2.4 Recent Development
15.3 Seqirus
15.3.1 Business Overview
15.3.2 Influenza Vaccines Portfolios
15.3.3 Recent Development
15.4 AstraZeneca
15.4.1 Business Overview
15.4.2 Influenza Vaccines Portfolio
15.4.3 Influenza Vaccines Sales Value Analysis
15.4.4 Recent Development
2. UNITED STATES INFLUENZA VACCINES MARKET SIZE & ANALYSIS (2013 - 2025)
3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2013 - 2025)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES INFLUENZA VACCINES MARKET
4.1 Market Drivers
4.2 Market Restraints
5. UNITED STATES INFLUENZA VACCINES PRICING TRENDS & ANALYSIS
6. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES)
7. UNITED STATES INFLUENZA VACCINES DISTRIBUTION & DEMAND (2010 - 2019)
8. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES (2004 – 2019)
9. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA
10. DISTRIBUTION CHANNEL & TECHNIQUE OF INFLUENZA VACCINATION IN UNITED STATES
11. UNITED STATES INFLUENZA VACCINES REIMBURSEMENT POLICIES & REGULATORY SYSTEM
11.1 Reimbursement Policies
11.2 Regulation System
12. MAJOR DEALS IN THE INFLUENZA VACCINES MARKET
12.1 Merger & Acquisitions
12.2 Collaboration Deal
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Distribution Agreement
13. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT
14. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY
14.1 Year 2018
14.2 Year 2017
15. KEY COMPANIES ANALYSIS
15.1 Sanofi Pasteur
15.1.1 Business Overview
15.1.2 Influenza Vaccines Portfolio
15.1.3 Influenza Vaccines Sales Value Analysis
15.1.4 Recent Development
15.2 GlaxoSmithKline (GSK)
15.2.1 Business Overview
15.2.2 Influenza Vaccines Portfolio
15.2.3 Influenza Vaccines Sales Value Analysis
15.2.4 Recent Development
15.3 Seqirus
15.3.1 Business Overview
15.3.2 Influenza Vaccines Portfolios
15.3.3 Recent Development
15.4 AstraZeneca
15.4.1 Business Overview
15.4.2 Influenza Vaccines Portfolio
15.4.3 Influenza Vaccines Sales Value Analysis
15.4.4 Recent Development
LIST OF TABLES:
Table 5–1: United States Pediatric Influenza Vaccines Price, 2019 – 2020
Table 5–2: United States Adult Influenza Vaccine Price, 2019 – 2020
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2019
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 11–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 12–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 12–2: Collaboration Deal in the Influenza Vaccines Market
Table 12–3: Licensing Agreement in the Influenza Vaccines Market
Table 12–4: Exclusive Agreement in the Influenza Vaccines Market
Table 12–5: Distribution Agreement in the Influenza Vaccines Market
Table 5–1: United States Pediatric Influenza Vaccines Price, 2019 – 2020
Table 5–2: United States Adult Influenza Vaccine Price, 2019 – 2020
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2019
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 11–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 12–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 12–2: Collaboration Deal in the Influenza Vaccines Market
Table 12–3: Licensing Agreement in the Influenza Vaccines Market
Table 12–4: Exclusive Agreement in the Influenza Vaccines Market
Table 12–5: Distribution Agreement in the Influenza Vaccines Market
LIST OF FIGURES:
Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2018
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2019 – 2025
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2018
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2025
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2018
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2019 – 2025
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2018
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2019 – 2025
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2019
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2018 - 2019
Figure 15–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2018
Figure 15–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2025
Figure 15–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2018
Figure 15–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2025
Figure 15–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2018
Figure 15–6: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2025
Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2018
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2019 – 2025
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2018
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2025
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2018
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2019 – 2025
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2018
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2019 – 2025
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2019
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2018 - 2019
Figure 15–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2018
Figure 15–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2025
Figure 15–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2018
Figure 15–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2025
Figure 15–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2018
Figure 15–6: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2025
